LATEST TWEETS - CURATED BY HASH FINANCE

brendan (brendan_49) 4 hours ago
5/ $XFOR conclusion: -ppl expect their bubble boy programs to work, but small risk/time adjusted opportunity. -Wal… https://t.co/P6aYrDxN2f
brendan (brendan_49) 4 hours ago
4/ The next $XFOR read-out in cancer wouldn't be until 2H20. But that's a setting - Waldenstrom's Macroglobulinemia… https://t.co/svydOzGZrq
brendan (brendan_49) 4 hours ago
3/ A prior ph1 n=9 $XFOR study of mavo+opdivo in RCC patients who failed to respond to opdivo alone was meh. [see f… https://t.co/rNVWeJloB4
brendan (brendan_49) 4 hours ago
2/ The $XFOR drug has 2 relevant MoAs to cancer. One is as an immune stimulant - it mobilizes immune cells. The oth… https://t.co/wj9IbSQ0at
brendan (brendan_49) 4 hours ago
1/ $XFOR has some cancer data in 11 days. Who are they? Reverse merger 👌 w/ an *oral* CXCR4 inhibitor called mavori… https://t.co/Hj0a8rHGqA
X4 Pharmaceuticals, Inc. (XFOR)'s Stock Is Buy After Today's Big Increase – The MAK Daily https://t.co/moLWe1afnK
$XFOR - VOLUME ALERT - 108 x expected rate per minute
$XFOR X4 Pharmaceuticals Appoints Renato Skerlj, Ph.D. as Senior Vice President of Research and Development https://t.co/9H4DKui4PA
$XFOR: X4 Pharmaceuticals Appoints Renato Skerlj, Ph.D. as Senior Vice …: https://t.co/RiH3UCwBfe
X4 Pharmaceuticals Appoints Renato Skerlj Ph.D. as Senior Vice President of Research and Development: X4 Pharmaceut… https://t.co/VQ2BjtGuYX
#X4Pharmaceuticals to Attend Two Upcoming Investor Conferences $XFOR https://t.co/31MviMzvOF
X4 Pharmaceuticals $XFOR Stock Rating Upgraded by Zacks Investment Research https://t.co/OymMMGGWYM
Recent $XFOR technical alerts: Pocket Pivot plus 12 more alerts... https://t.co/PuIiM1v4r5
X4 Pharmaceuticals $XFOR Lifted to Hold at Zacks Investment Research https://t.co/5ljl1bIsIs
$XFOR Just moved up on higher volume. break out. 12 Sept: -will present clinical data on its lead product candidat… https://t.co/iuqFRnFlRJ
#X4Pharmaceuticals to Present Phase 2a Data for #Mavorixafor in Combination with #Axitinib at European Society for… https://t.co/UxjuB3hg9q
$XFOR X4 Pharmaceuticals to Present Phase 2a Data for Mavorixafor in Combination with Axitinib at European Society… https://t.co/DLmW3eYWe3
$XFOR: X4 Pharmaceuticals to Present Phase 2a Data for Mavorixafor in …: https://t.co/djqwL7MS1V